UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
September 26, 2006
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
750
Lexington Avenue, 20th
Floor
New
York, New York 10022
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x
Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o
No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Annual
General Meeting ("AGM") Notice Posted to Shareholders
New
York, New York, September 26, 2006 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biotechnology
company focused on the acquisition, development and commercialization of
pharmaceutical products for the treatment of infectious diseases, particularly
the treatment of hepatitis C, has posted to shareholders a notice convening
its
AGM. The AGM will take place at the Conference Room at the Company’s Israeli
offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100,
at
4:00 p.m., on October 25, 2006.
At
the
AGM it is proposed that:
| · |
the
annual reports for the year ended 31 December 2005 be received;
|
| · |
Kesselman
& Kesselman (PricewaterhouseCoopers) be reappointed as the Company's
auditors; and
|
| · |
Messrs
Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed
as
Directors of the Company.
|
Contacts:
XTL
Ron
Bentsur, Chief Executive Officer
Tel:
+1
(212) 531-5960
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
is
engaged in the acquisition, development and commercialization of therapeutics
for the treatment of infectious diseases, with a focus on hepatitis C. XTL
is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase - presently in Phase 1 clinical trials in patients
with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of
two
monoclonal antibodies against the hepatitis C virus - presently in Phase 1
clinical trials in patients with chronic hepatitis C. XTL’s hepatitis C pipeline
also includes several families of pre-clinical hepatitis C small molecules.
XTL
is publicly traded on the Nasdaq, London, and Tel-Aviv Stock Exchanges (NASDAQ:
XTLB; LSE: XTL; TASE: XTL).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: September 26, 2006 | By: | /s/ Ron Bentsur |
|
Ron Bentsur |
||
| Chief Executive Officer | ||